|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusions and V600E point mutations, are associated primarily with pilocytic astrocytomas and nonpilocytic gliomas, respectively.
|
21884820 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusions and V600E point mutations, are associated primarily with pilocytic astrocytomas and nonpilocytic gliomas, respectively.
|
21884820 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using the BRAF(V600E)-specific inhibitor PLX4720, pharmacologic blockade of BRAF revealed preferential antiproliferative activity against BRAF(V600E) mutant cells in vitro, in contrast to the use of shRNA-mediated knockdown of BRAF, which inhibited cell growth of glioma cell lines regardless of BRAF mutation status.
|
22038996 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using the BRAF(V600E)-specific inhibitor PLX4720, pharmacologic blockade of BRAF revealed preferential antiproliferative activity against BRAF(V600E) mutant cells in vitro, in contrast to the use of shRNA-mediated knockdown of BRAF, which inhibited cell growth of glioma cell lines regardless of BRAF mutation status.
|
22038996 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, a previous study on BRAF V600E mutation in paediatric glioma revealed a BRAF mutation in one of two tested DIAs/DIGs.
|
23822828 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, a previous study on BRAF V600E mutation in paediatric glioma revealed a BRAF mutation in one of two tested DIAs/DIGs.
|
23822828 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF blockade with UAI-201 resulted in dose-dependent inhibition of MEK/ERK phosphorylations and increased G0/G1 arrest in glioma cells with BRAF-V600E.
|
24721513 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF blockade with UAI-201 resulted in dose-dependent inhibition of MEK/ERK phosphorylations and increased G0/G1 arrest in glioma cells with BRAF-V600E.
|
24721513 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoastrocytoma with anaplastic feature was suggested based on the association of some pathological feature (eosinophilic granular bodies, reticulin network and diffuse CD34 expression) and the BRAF V600E mutation.
|
24857351 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoastrocytoma with anaplastic feature was suggested based on the association of some pathological feature (eosinophilic granular bodies, reticulin network and diffuse CD34 expression) and the BRAF V600E mutation.
|
24857351 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neuronal component or differentiation.
|
25346165 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neuronal component or differentiation.
|
25346165 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrated that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with BRAF(V</span>600E</span>) in</span>hibitor PLX4720 to reduce MAPK and Akt signaling, resulting in decreased glioma cell viability.
|
26023796 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrated that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with BRAF(V</span>600E</span>) in</span>hibitor PLX4720 to reduce MAPK and Akt signaling, resulting in decreased glioma cell viability.
|
26023796 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
|
26384810 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
|
26384810 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma.
|
26414224 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma.
|
26414224 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We discuss differential diagnosis of the tumor, and review previously described diffuse gliomas with the BRAF V600E mutation.
|
26445861 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We discuss differential diagnosis of the tumor, and review previously described diffuse gliomas with the BRAF V600E mutation.
|
26445861 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes.
|
27350555 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes.
|
27350555 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We were unable to find other examples of glial tumors in public databases with this rare BRAF V600D mutation.
|
27860162 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation.
|
28062673 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation.
|
28062673 |
2017 |